Analyst firms · Wolfe Research · MRK

Wolfe Research MRK price target and rating history

Merck & Company Inc. (MRK) · Health Care

Wolfe Research rates Merck & Company Inc. (MRK) Outperform with a $135 price target, as of its latest action on Jan 8, 2026. It has published 3 rating actions on MRK since February 2023, including 2 upgrades and 0 downgrades. Across 11 firms with a MRK price target in the last 12 months, the median target is $140. Wolfe Research's $135 is 4% below that.

Current rating
Outperform
Price target
$135
Median target, all firms
$140
Actions on MRK
3

Wolfe Research price target on MRK

$135$131$127202420252026
Wolfe Research price target on MRK, each point a stated target, February 2023 to January 2026.

Every Wolfe Research rating on MRK

How other firms rate MRK

Each firm's latest rating and stated target in the last 12 months.

FirmRatingPrice targetDate
DZ BankHold$153Nov 3, 2026
RBC Capital MarketsSector Perform$150Aug 20, 2026
Morgan StanleyOverweight$179Aug 20, 2026
DaiwaOutperform$143Aug 12, 2026
CitigroupNeutral$125May 6, 2026
BarclaysOverweight$140Feb 20, 2026
Deutsche BankBuy$150Feb 13, 2026
Wolfe ResearchOutperform$135Jan 8, 2026
BMO Capital MarketsOutperform$130Dec 18, 2025
Wells FargoOverweight$125Nov 24, 2025
ScotiabankSector Outperform$105Nov 13, 2025

Questions about Wolfe Research and MRK

What is Wolfe Research's price target for MRK?
Wolfe Research's latest stated price target for Merck & Company Inc. (MRK) is $135, from its action on Jan 8, 2026.
What is Wolfe Research's rating on MRK?
Wolfe Research rates MRK Outperform, a bullish rating, as of Jan 8, 2026.
When did Wolfe Research last change its view on MRK?
On Jan 8, 2026, Wolfe Research upgrades to Outperform from Peer Perform, price target $135.
How does Wolfe Research's MRK target compare with other analysts?
Across 11 firms with a MRK price target in the last 12 months, the median target is $140. Wolfe Research's $135 is 4% below that.

More MRK rating histories

All Wolfe Research ratingsMRK news and filingsEvery analyst firm

From rating actions in the Quantisnow feed. A target holds until the firm states a new one; a reiteration with no target keeps the last one. Not investment advice.